PRQR — ProQR Therapeutics NV Income Statement
0.000.00%
Last trade - 00:00- $214.34m
- $65.03m
- €19.55m
- 33
- 14
- 36
- 16
Annual income statement for ProQR Therapeutics NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 9.45 | 2.38 | 4.36 | 9.53 | 19.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 51.8 | 59.6 | 70.9 | 39.5 | 50 |
| Operating Profit | -42.4 | -57.2 | -66.5 | -30 | -30.5 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -46.5 | -60.7 | -64.1 | -27.8 | -28 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -46.6 | -60.8 | -64.2 | -27.7 | -27.8 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -46.6 | -60.7 | -64.4 | -28.1 | -27.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -46.6 | -60.7 | -64.4 | -28.1 | -27.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.93 | -0.946 | -0.887 | -0.363 | -0.323 |